| x | ANNUAL      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|---|------------------------------------------------------------------------------------------------|

| o | TRANSITION      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF      1934 |
|---|----------------------------------------------------------------------------------------------------|

----

|          |          |                                                                                                                      |   |
|---------------|---------------|---------------------------------------------------------------------------------------------------------------------------|--------|
| Part      I   | Item      1.  | Description      of Business                                                                                              | 3      |
|          | Item      2.  | Description      of Property                                                                                              | 6      |
|          | Item      3.  | Legal      Proceedings                                                                                                    | 6      |
|          | Item      4.  | Submission      of Matters to a Vote of Security Holders                                                                  | 6      |
|          |          |                                                                                                                      |   |
| Part      II  | Item      5.  | Market      for Common Equity and Related Stockholder Matters                                                             | 7      |
|          | Item      6.  | Management’s      Discussion and Analysis and Results of Operations and Financial      Condition                    | 8      |
|          | Item      7.  | Financial      Statements                                                                                                 | 9      |
|          | Item      8.  | Changes      in and Disagreements with Accountants on Accounting and Financial      Disclosure                            | 16     |
|          | Item      8A. | Controls      and Procedures                                                                                              | 16     |
|          | Item      8B. | Other      Information                                                                                                    | 16     |
|          |          |                                                                                                                      |   |
| Part      III | Item      9.  | Directors,      Executive Officers, Promoters and Control Persons, Compliance with Section      16(a) of the Exchange Act | 17     |
|          | Item      10. | Executive      Compensation                                                                                               | 19     |
|          | Item      11. | Security      Ownership of Certain Beneficial Owners and Management                                                       | 19     |
|          | Item      12. | Certain      Relationships and Related Party Transactions                                                                 | 19     |
|          | Item      13. | Exhibits                                                                                                                  | 20     |
|          | Item      14. | Principal      Accountant Fees and Services                                                                               | 21     |

----

Further, this report contains forward looking statementswithin the meaning of Section 27A of the Securities Act and Section 21E of theSecurities Exchange Act that involve substantial risks anduncertainties.  Such statements include, without limitation, allstatements as to expectation or belief and statements as to the Company’s futureresults of operations, the progress of any research, product development andclinical programs, the need for, and timing of, additional capital and capitalexpenditures, partnering prospects, the protection of and the need foradditional intellectual property rights, effects of regulations, the need foradditional facilities and potential market opportunities.  TheCompany’s actual results may vary materially from those contained in suchforward-looking statements because of risks to which the Company is subject,such as lack of available funding, competition from third parties, intellectualproperty rights of third parties, regulatory constraints, litigation and otherrisks to which the Company is subject.

----

ITEM 1. DESCRIPTION OF BUSINESS

----

| ·  | provide      enough data for statistical proof of safety and  efficacy; |
|--------------|-------------------------------------------------------------------------|
| ·  | compare      the experimental therapy to existing therapies;            |
| ·  | uncover      any unexpected safety problems, such as side-effects;  and |
| ·  | generate      product labeling.                                         |

----

----

ITEM 2. DESCRIPTION OF PROPERTY

ITEM 3. LEGAL PROCEEDINGS - NONE

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS -NONE

----

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDERMATTERS

----

ITEM 6. MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OFOPERATIONS AND FINANCIAL CONDITION

----

----

ITEM 7. FINANCIAL STATEMENTS

----

|                                                                                                  |                                                                        |                                                                        |
|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|                                                                                                  | March31,                                                                    |
|                                                                                                  | 2008                                                                        | 2007                                                                        |
|                                                                                                  |                                                                        |                                                                        |
| ASSETS                                                                                                |                                                                        |                                                                        |
|                                                                                                  |                                                                        |                                                                        |
| Current    assets:                                                                                    |                                                                        |                                                                        |
|     Cash and      cash equivalents                                                | $      --                                     | $       --                               |
| Totalassets                                                                                           | $       --                                    | $       --                                    |
|                                                                                                  |                                                                        |                                                                        |
| LIABILITIES      AND SHAREHOLDERS' DEFICIT                                                            |                                                                        |                                                                        |
|                                                                                                  |                                                                        |                                                                        |
| Current      liabilities:                                                                             |                                                                        |                                                                        |
|     Accounts      payable and accrued      liabilities                            | 136,919                                                                     | 101,372                                                                     |
|     Convertible      note payable, net                                            | 20,914                                                                      | 20,914                                                                      |
|         Total      current liabilities                        | 157,833                                                                     | 122,286                                                                     |
| Commitments and      contingencies                                                                    | --                                                                          | --                                                                          |
| Shareholders'      deficit:                                                                           |                                                                        |                                                                        |
|     Preferred      stock, no par value,      10,000,000 shares authorized,        |                                                                        |                                                                        |
|       no      shares issued or outstanding                              | --                                                                          | --                                                                          |
|     Common      stock, no par value, 500,000,000 shares authorized,               |                                                                        |                                                                        |
|       81,352,500 issued and outstanding at      March 31, 2008 and 2007 | 1,000                                                                       | 1,000                                                                       |
|     Deficit      accumulated in the      development stage                        | (158,833)                                                                   | (123,286)                                                                   |
|          Total      shareholders’ deficit          | (157,833)                                                                   | (122,286)                                                                   |
| Total liabilities and      shareholders' deficit                                                      | $            -- | $            -- |

----

|                                                                   |                                                                              |                                                                              | Inception                                                                          |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
|                                                                   | Year Ended                                                                        | Year Ended                                                                        | (February 15, 2005)      to                                                        |
|                                                                   | March 31,    2008                                                                 | March 31,    2007                                                                 | March 31, 2007                                                                     |
|                                                                   |                                                                              |                                                                              |                                                                               |
| General and administrative      expenses                               | $       33,663                                 | $       47,499                                 | $            155,225   |
|                                                                   |                                                                              |                                                                              |                                                                               |
| Loss from      operations                                              | (33,663)                                                                          | (47,499)                                                                          | $            (155,225) |
|                                                                   |                                                                              |                                                                              |                                                                               |
| Other income      (expense)                                            |                                                                              |                                                                              |                                                                               |
|   Interest      expense                                      | (1,884)                                                                           | (1,724)                                                                           | $            (3,608)   |
|                                                                   |                                                                              |                                                                              |                                                                               |
| Net loss                                                               | $    (35,547)                                                 | $    (49,223)                                                 | $            (158,833) |
|                                                                   |                                                                              |                                                                              |                                                                               |
| Net loss per      share:                                               |                                                                              |                                                                              |                                                                               |
|         Basic      and diluted | $             -- | $             -- |                                                                               |
|                                                                   |                                                                              |                                                                              |                                                                               |
| Weighted average number of common      shares                          |                                                                              |                                                                              |                                                                               |
|   outstanding:                                               |                                                                              |                                                                              |                                                                               |
|         Basic      and diluted | 81,352,500                                                                        | 81,352,500                                                                        |                                                                               |

----

|                                                                        |       |                                                         |                                                | Deficit                                            |                                                     |
|-----------------------------------------------------------------------------|------------|--------------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------|
|                                                                        |       |                                                         |                                                | Accumulated                                        |                                                     |
|                                                                        |       |                                                         | Stock                                               | During      the                                    |                                                     |
|                                                                        |       |                                                         | Subscription                                        | Development                                        |                                                     |
|                                                                        | Shares     | Amount                                                       | Receivable                                          | Stage                                              | Total                                                    |
| Balance      – March 31, 2005                                         | 81,352,500 | $         1,000 | $    (1,000)                    | $       (1,792) | $        (1,792) |
| Collection      of stock subscription    receivable     | --         | --                                                           | 1,000                                               | --                                                 | 1,000                                                    |
| Net      loss for the year ended    March      31, 2006 | --         | –                                                      | --                                                  | (72,271)                                           | (72,271)                                                 |
| Balance      – March 31, 2006                                         | 81,352,500 | $        1,000       | $        -- | $     (74,063)            | $     (73,063)                  |
| Net      loss for the year ended   March      31, 2007       | --         | --                                                           | --                                                  | (49,223)                                           | (49,223)                                                 |
| Balance      – March 31, 2007                                         | 81,352,500 | $       1,000             | $       --       | $    (123,286)                 | $    (122,286)                       |
| Net      loss for the year ended   March      31, 2008       | --         | --                                                           | --                                                  | (35,547)                                           | (35,547)                                                 |
| Balance      – March 31, 2008                                         | 81,352,500 | $       1,000             | $       --       | $    (158,833)                 | $    (157,833)                       |

----

|                                                                                                                                          |                              |                                                                              | Inception                                |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------------------------------------------------------|------------------------------------------|--------|
|                                                                                                                                          | Year Ended                        | Year Ended                                                                        | (February 15,      2005)                 |   |
|                                                                                                                                          | March 31, 2008                    | March 31, 2007                                                                    | to March 31, 2008                        |   |
| Cash flows from operating      activities:                                                                                                    |                              |                                                                              |                                     |   |
|     Net      loss                                                                                                         | $   (35,547)  | $     (49,223)                                           | $     (158,833) |   |
|     Adjustments to reconcile net loss to      cash used in      operating      activities:  |                              |                                                                              |
|         Changes      in assets and liabilities:                                                       |                              |                                                                              |                                     |   |
|             Increase (decrease) in      accounts payable and      accrued expense |  35,547                      |  26,365                                                                      |  136,919                            |   |
| Net cash provided by operating      activities                                                                                                | --                                | (22,858)                                                                          | (21,914)                                 |   |
| Cash flows from investing      activities                                                                                                     | --                                | --                                                                                | --                                       |   |
| Cash flows from financing      activities:                                                                                                    |                              |                                                                              |                                     |   |
|     Collection      of stock subscription receivable                                                                      | --                                | --                                                                                | 1,000                                    |   |
|     Proceeds      from issuance of convertible notes                                                                      | --                                | 25,000                                                                            | 25,000                                   |   |
|     Repayment of      convertible notes payable                                                                           | --                                | (4,086)                                                                           | (4,086)                                  |   |
| Net cash provided by financing      activities                                                                                                | --                                | 20,914                                                                            | 21,914                                   |   |
| Net increase (decrease) in cash and cash      equivalents                                                                                     | --                                | (1,944)                                                                           | --                                       |   |
| Cash and cash equivalents,      beginning of period                                                                                           | --                                | 1,944                                                                             | --                                       |   |
| Cash and cash equivalents, end of      period                                                                                                 | $     -- | $             -- | $     --        |   |

| Supplemental cash flow      information:                   |                                                                        |                                                                        |                                                                        |
|------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
|     Interest      paid                 | $            -- | $            -- | $            -- |
|     Taxes      paid                    | $            -- | $            -- | $            -- |
|                                                       |                                                                        |                                                                        |                                                                        |
|     Stock      subscription receivable | $            -- | $            -- | $            -- |

----

----

----

|                                                         |   | March      31, 2008 |    |
|--------------------------------------------------------------|--------|---------------------|---------|
| Deferred      tax assets attributable to:                    |   |                |    |
|     Net      operating loss carryforward |   | $                   | 12,100  |   |
| Less:  Change      in valuation allowance          |   |                | (12,100 | ) |
| Net      deferred tax assets                                 |   | $                   | --      |   |

----

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTINGAND FINANCIAL DISCLOSURE

ITEM 8A. CONTROLS AND PROCEDURES

ITEM 8B. OTHER INFORMATION

----

|   | ITEM      9.  DIRECTORS, EXECUTIVER OFFICERS, PROMOTERS AND CONTROL      PERSONS, COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE  ACT |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------|

| Name                  |   | Age |   | Position                                                         |
|-----------------------|--------|-----|--------|------------------------------------------------------------------|
| J.      Leonard Ivins |   | 71  |   | Chief      Executive Officer, Secretary, Treasurer and  Director |

| ·  | evaluates      the Company’s independent auditors’ qualifications, independence and      performance;                                       |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| ·  | determines      the engagement of the independent auditors;                                                                                             |
| ·  | approves      the retention of the Company’s independent auditors to perform any      proposed permissible non-audit services;                    |
| ·  | reviews      the Company’s financial statements;                                                                                                  |
| ·  | reviews      the Company’s critical accounting policies and  estimates;                                                                           |
| ·  | oversees      the internal audit function; and                                                                                                          |
| ·  | discusses      with management and the independent auditors the results of the annual      audit and the review of the quarterly financial  statements. |

----

| ·  | reviewing      and recommending policy relating to compensation and benefits of the      Company’s officers and employees;                                             |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ·  | reviewing      and approving corporate goals and objectives relevant to the compensation      of the Company’s chief executive officer and other senior      officers; |
| ·  | evaluating      the performance of these officers in light of those goals and objectives;      and                                                                           |
| ·  | setting      compensation of these officers based on such  evaluations.                                                                                                      |

| ·   | the      name and address, as they appear on the Company’s books, of the      stockholder giving the notice and of the beneficial owner, if any, on      whose behalf the nomination is made;                                                                                                                                                                                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ·   | a      representation that the stockholder giving the notice is a holder of      record of the Company’s stock entitled to vote at the annual meeting and      intends to appear in person or by proxy at the annual meeting to nominate      the person or persons specified in the notice;                                                                                                 |
| ·   | a      complete biography of the nominee, as well as consents to permit the      Company to complete any due diligence investigations to confirm the      nominee’s background, as the Company believes to be      appropriate;                                                                                                                                                              |
| ·   | a      description of all litigation to which the nominee or any of his or her      affiliates have been a party within the past ten years;                                                                                                                                                                                                                                                        |
| ·   | the      disclosure of all special interests and all political and organizational      affiliations of the nominees;                                                                                                                                                                                                                                                                               |
| ·   | a      signed, written statement from the director nominee as to why the director      nominee wants to serve on the Company’s Board of Directors and why the      director nominee believes that he or she is qualified to      serve;                                                                                                                                                      |
| ·   | a      description of all arrangements or understandings between or among any of      the stockholders giving the notice, the beneficial owner, if any, on whose      behalf the notice is given, each nominee and any other person or persons      (naming such person or persons) pursuant to which the nomination or      nominations are to be made by the stockholder giving the      notice; |
| ·   | such      other information regarding each nominee proposed by the stockholder      giving the notice as would be required to be included in a proxy statement      filed pursuant to the proxy rules of the Securities and Exchange      Commission; and                                                                                                                                          |
| ·   | the      signed consent of each nominee to serve as a director of the Company if so      elected.                                                                                                                                                                                                                                                                                                  |

----

ITEM 10. EXECUTIVE COMPENSATION

| · | each      person who is known by the Company to be the beneficial owner of more than      5% of its outstanding shares of common stock; |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------|
| · | each      of the Company’s directors;                                                                                             |
| · | each      of the Company’s named executive officers; and                                                                          |
| · | all      of the Company’s directors and executive officers as a    group.                                                         |

|  Name      and Address of Beneficial Owner                    |   | Number of      Shares Beneficially Owned |       | Percentage      of Outstanding Shares |   |
|--------------------------------------------------------------------|--------|------------------------------------------|------------|---------------------------------------|--------|
| J.      Leonard Ivins, CEO and Director (1)                        |   |                                     | --         |                                  |   | -- | % |
| Directors      and Executive Officers as a Group (2 persons)  |   |                                     | --         |                                  |   | -- | % |
|                                                               |   |                                     |       |                                  |   |   |   |
| Silver      Star Holdings Trust (2)                           |   |                                     | 66,430,000 |                                  |   | 81.7 | % |
| Carl      A. Chase (3)                                        |   |                                     | 6,570,000  |                                  |   | 8.1 | % |

| (1)   | Mr.      Ivins’ business address is 2036 Brentwood Drive, Houston, Texas      77019.                                                                                                                                                    |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)   | Mr.      Kevan Casey exercises voting and dispositive power of all shares      beneficially owned by Silver Star Holdings Trust.  Mr. Casey’s      business address is 5075 Westheimer, Suite 975, Houston, Texas      77056. |
| (3)   | Mr.      Chase’s business address is 5075 Westheimer, Suite 975, Houston, Texas      77056.                                                                                                                                             |

----

ITEM 13. EXHIBITS

| Exhibit      No.      | Description                                                                                                                                                                                                                                                                                                                                                |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1*                  | Articles      of Incorporation (incorporated by reference to Exhibit 3.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                                                                                           |
| 3.2*                  | Bylaws      of Tabatha I, Inc. (incorporated by reference to Exhibit 3.2 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                                                                                           |
| 4.1*                  | Specimen      of Stock Certificate (incorporated by reference to Exhibit 4.1 from      Registration Statement on Form-SB filed with the Securities and Exchange      Commission on October 11, 2000)                                                                                                                                                       |
| 4.2*                  | Specimen      Class A Convertible Preferred Stock Certificate (incorporated by reference      to Exhibit 4.2 from Registration Statement on Form-SB filed with the      Securities and Exchange Commission on October 11, 2000)                                                                                                                            |
| 14.1*                 | Code      of Ethics (incorporated by reference to Exhibit 14.1 to Registrant’s Form      10-KSB filed with the Securities and Exchange Commission on June 29,      2005)                                                                                                                                                                             |
| 10.1*  10.2 | Exchange      Agreement between Interactive Therapeutics, Inc. (formerly Tabatha I,      Inc.) and Zigen, Inc. dated February 25, 2005 (incorporated by reference      to Exhibit 10.1 to Registrant’s Form 8-K filed with the Securities and      Exchange Commission of May 31, 2005)License      agreement with Prochem Szeja dated July 10, 2008 |
|                  |                                                                                                                                                                                                                                                                                                                                                       |
|                  |                                                                                                                                                                                                                                                                                                                                                       |
| 31.1                  | Certification      pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act      of 1934, as amended (filed herewith)                                                                                                                                                                                                                     |
| 32.1                  | Certification      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of      the Sarbanes-Oxley Act of 2002 (filed herewith)                                                                                                                                                                                                          |
|                  |                                                                                                                                                                                                                                                                                                                                                       |

----

ITEM14.                      PRINCIPALACCOUNTANT FEES AND SERVICES

----

| Signature                                         | Title                                                                      | Date               |
|---------------------------------------------------|----------------------------------------------------------------------------|--------------------|
| By:  /s/  J. Leonard    Ivins | Chief      Executive Officer, Principal Accounting Officer and    Director | July      15, 2008 |
|     J.      Leonard Ivins     |                                                                       |               |
|                                              |                                                                       |               |

----

| 1.   | Moreover, the Licensor represents      as follows: |
|----------------|----------------------------------------------------|

| a.   | the subject of the invention has      been developed by PROCHEMSZEJA, |
|----------------|-----------------------------------------------------------------------|

| b.   | no circumstances exist whatsoever      that would constrain the Licensor’s right to conclude this Agreement under      the provisions statedherein, |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | according to the Licensor’s best      knowledge there is a possibility of use and commercial exploitation of the      subject of the invention, |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | before the date of this Agreement      the Licensor did not submit to the Patent Office any declaration of open      license in relation to theinvention, |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| e.   | the subject of the invention does      not infringe on any third parties’ rights    whatsoever, |
|----------------|-------------------------------------------------------------------------------------------------------|

| f.   | any and all required fees      associated with the filing of the application with the Polish Patent      Office and any and all current fees associated with the proceedings before      the European Patent Office have been duly  paid. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.   | The Licensee shall have the right      to use the invention within all of its divisions, branches, plants, units      that form part of the Licensee’s organizational      structure. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.   | Upon signing of this Agreement the      Licensee shall pay to the Licensor a license fees in the amount of US$      15,000. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------|

| 2.   | During the first 3 years of this      Agreement the Licensee shall pay to the Licensor license fees in the      amount of US$ 25,000 per annum starting on July 11,      2009. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | During the life of this Agreement      starting on July 11, 2012 the Licensee shall pay to the Licensor license      fees in the amount of US$ 40,000 per  annum |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | All subsequent license fees shall      be payable no later than on the last day of the month falling after the      subsequent settlementperiod. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | Should the Licensee be in default      of payments of the license fees, the Licensor shall be entitled to charge      the Licensee with interest for default at legal    rate. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.   | The license fees and any and all      other payments to be made by the Licensee to the Licensor in connection      with this Agreement shall be paid into the Licensor’s bank  Bank      PKO BP SA  account number 48 1020 2401 0000 0102 0182      8292 |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.   | The Licensor has the right to      change the bank account into which payments are to be effected. Such      change shall be binding for the Licensee from the date of receipt by the      Licensee of the notification made by the  Licensor. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.   | Milestone payments will be as      follows: |
|----------------|---------------------------------------------|

| 1.   | The Licensee      shall: |
|----------------|--------------------------|

| a.   | immediately notify the Licensor in      writing of any infringement by third parties, or by Licensee’s employees,      of Licensor’s or Licensee’s rights related to the      invention, |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | keep secret all information      related to the project obtained from the Licensor or acquired from      technical documentation, except where disclosure of such information is      required by the law, |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | keep and maintain technical      documentation in a manner precluding access thereto by third      parties, |
|----------------|-------------------------------------------------------------------------------------------------------------|

| d.   | provide organizational, technical      and legal conditions to ensure effective protection against access by      third parties to any information concerning the invention, obtained from      the Licensor or acquired from technical    documentation. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | Provisions of Art. 6.1.b shall      remain in force after the termination of this Agreement for a period of      five years. |
|----------------|------------------------------------------------------------------------------------------------------------------------------|

| 3.   | The only persons entitled to      access the project under this Agreement are the Licensee’s employees and      Licensee’s duly authorizedagents. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | All persons entitled to access the      project shall be duly instructed by the Licensee about the duty of      secrecy. |
|--------|--------------------------------------------------------------------------------------------------------------------------|

----

| 1.   | The Licensor is entitled to      immediately terminate this Agreement, upon written notice, in the event      of: |
|----------------|-------------------------------------------------------------------------------------------------------------------|

| a.   | breach by the Licensee of the      provisions of Art. 3 above, |
|----------------|----------------------------------------------------------------|

| b.   | the Licensee failing to pay a      license fees. |
|----------------|--------------------------------------------------|

| 2.   | Should the Licensor terminate this      Agreement, the Licensee is obliged to immediately pay all license fees      accruable on the date of termination along with all due interests referred      to in Art. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.   | The Licensee is entitled to      immediately terminate this Agreement, upon written notice, in the event      of: |
|----------------|-------------------------------------------------------------------------------------------------------------------|

| a.   | granting by the Licensor of a      license to use the invention to a third  party, |
|----------------|------------------------------------------------------------------------------------|

| b.   | inability to use the project for      the Licensee’s needs defined under Art. 2.1  above, |
|----------------|-------------------------------------------------------------------------------------------------|

| c.   | failure of the Licensor to meet      its obligations defined under Art. 6  above, |
|----------------|-----------------------------------------------------------------------------------|

| d.   | any of the representations of the      Licensor given in Art. 1 above proving to be  untrue. |
|----------------|----------------------------------------------------------------------------------------------|

| 2.   | Should this Agreement be      terminated by the Licensee due to reasons specified under item 1 above,      the Licensor shall be obliged to repay all license fees obtained under      Art. 5.3 above. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | Then      I have reviewed this annual report on Form 10-K of Interactive      Therapeutics, Inc.; |
|----|---------------------------------------------------------------------------------------------------|

|   | 2.   Based      on my knowledge, this annual report does not contain any      untrue  statement of a material fact or omit to state a material      fact necessary to  make the statements made, in light of the      circumstances under which      such      statements were made, not      misleading with respect to the period covered by this annual      report; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Based      on my knowledge, the financial statements, and other      financial  information included in this annual report, fairly      present in all material respects the financial condition, results of      operations and cash flows of the registrant as of, and for, the periods      presented in this annual report; |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.  The      registrant's other certifying officers and I are responsible for      establishing and maintaining disclosure controls and procedures (as      defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and      have: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | designed      such disclosure controls and procedures to ensure that material      information relating to the registrant, including its consolidated      subsidiaries, is made known to us by others within those entities,      particularly during the period in which this annual  report is      being prepared; |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  b)   evaluated      the effectiveness of the registrant's disclosure controls and procedures      as of a date within 90 days prior to the filing date of  this      annual report (the "Evaluation Date");and |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c)  presented      in this annual report our conclusions about the effectiveness of the      disclosure controls and procedures based on our evaluation as of the      Evaluation Date; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The      registrant's other certifying officers and I have disclosed, based on our      most recent evaluation, to the registrant's auditors and the audit      committee of registrant's board of directors (or persons performing      the      equivalent    functions): |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a)   all      significant deficiencies in the design or operation of internal controls      which could adversely affect the registrant's ability      to  record, process, summarize and report financial data and      have identified for the registrant's auditors any material weaknesses in      internal controls; and |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b)   any      fraud, whether or not material, that involves management or other      employees who have a significant role in the registrant's internal      controls; and |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.   The      registrant's other certifying officers and I have indicated in this annual      report whether there were significant changes in      internal  controls or in other factors that could significantly      affect internal controls subsequent to the date of our most recent      evaluation, including any corrective actions with regard to significant      deficiencies and materialweaknesses. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

EXHIBIT  31.2 - CERTIFICATION OF CHIEFFINANCIAL OFFICER OF INTERACTIVE THERAPEUTICS, INC. REQUIRED BYRULE  13A - 14(1) OR RULE 15D - 14(A) OF THE SECURITIES EXCHANGE ACTOF  1934,  AS  ADOPTED  PURSUANT  TO  SECTION  302  OF  THE  SARBANES-OXLEY  ACTOF  2002.

| 1. | Then      I have reviewed this annual report on Form 10-K of Interactive      Therapeutics, Inc.; |
|----|---------------------------------------------------------------------------------------------------|

|   | 2.   Based      on my knowledge, this annual report does not contain any      untrue  statement of a material fact or omit to state a material      fact necessary to  make the statements made, in light of the      circumstances under which      such      statements were made, not      misleading with respect to the period covered by this annual      report; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Based      on my knowledge, the financial statements, and other      financial  information included in this annual report, fairly      present in all material respects the financial condition, results of      operations and cash flows of the registrant as of, and for, the periods      presented in this annual report; |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4.  The      registrant's other certifying officers and I are responsible for      establishing and maintaining disclosure controls and procedures (as      defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and      have: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | designed      such disclosure controls and procedures to ensure that material      information relating to the registrant, including its consolidated      subsidiaries, is made known to us by others within those entities,      particularly during the period in which this annual  report is      being prepared; |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |  b)   evaluated      the effectiveness of the registrant's disclosure controls and procedures      as of a date within 90 days prior to the filing date of  this      annual report (the "Evaluation Date");and |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c)  presented      in this annual report our conclusions about the effectiveness of the      disclosure controls and procedures based on our evaluation as of the      Evaluation Date; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The      registrant's other certifying officers and I have disclosed, based on our      most recent evaluation, to the registrant's auditors and the audit      committee of registrant's board of directors (or persons performing      the      equivalent    functions): |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a)   all      significant deficiencies in the design or operation of internal controls      which could adversely affect the registrant's ability      to  record, process, summarize and report financial data and      have identified for the registrant's auditors any material weaknesses in      internal controls; and |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b)   any      fraud, whether or not material, that involves management or other      employees who have a significant role in the registrant's internal      controls; and |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.   The      registrant's other certifying officers and I have indicated in this annual      report whether there were significant changes in      internal  controls or in other factors that could significantly      affect internal controls subsequent to the date of our most recent      evaluation, including any corrective actions with regard to significant      deficiencies and materialweaknesses. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Exhibit 32

|   | (i)  The  Report  fully  complies      with the requirements of Section 13(a) or      15(d)  of  the  Securities  Exchange  Act  of  1934;  and |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii)      The  information  contained  in  the  Report  fairly  presents,      in all  material  respects,  the financial      condition and results of operations      of  the  Company  as of the dates and for      the periods expressed in theReport. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----